Skip to content

Remimazolam or Dexmedetomidine for Sedation During Awake Fibreoptic Nasal Intubation: A Randomised Controlled Trial

Remimazolam or Dexmedetomidine for Sedation During Awake Fibreoptic Nasal Intubation: A Randomised Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031965
Enrollment
Unknown
Registered
2020-04-16
Start date
2020-12-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Difficult airway

Interventions

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 75 Years

Inclusion criteria

Inclusion criteria: oral and maxillofacial surgery patients in the First Affiliated Hospital of Zhengzhou University who had been scheduled to undergo nasal awake tracheal intubation, American Society of Anesthesiology classification of I or II, aged 12–75 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows: a history of allergy to benzodiazepines, flumazenil or dexmedetomidine, long-term use of sedatives or alcohol dependence, pregnant or lactating women, cognitive disorders or severe psychiatric or neurological disorders, and with inability to give their consent.

Design outcomes

Primary

MeasureTime frame
Intubation comfort;

Secondary

MeasureTime frame
Intubation time;vital signs;adverse reaction;sedation time;Number of attempts;

Countries

China

Contacts

Public ContactYanqiu Ai

The First Affiliated Hospital of Zhengzhou University

aiyanqiu82@163.com+86 13607690334

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026